Showing 7821-7830 of 9460 results for "".
- Vaseline Takes on Lack of Diversity in Skin Color Images with New Databasehttps://practicaldermatology.com/news/vaseline-takes-on-lack-of-diversity-in-skin-color-images-with-new-database/2461160/Vaseline is launching See My Skin, a database designed to search for conditions on skin of color and connect patients with dermatologists. Vaseline is introducing See My Skin with HUED, a digital health company focused on improving quality of care for Black, Latinx and Indigen
- Botox Cosmetic Turns 20!https://practicaldermatology.com/news/botox-cosmetic-turns-20/2461158/Allergan Aesthetics’ BOTOX Cosmetic (onabotulinumtoxinA) turns 20 on April 15, 2022. This date marks 20 years since the U.S. Food and Drug Administration (FDA) first approved the product to temporarily improve the look of moderate to severe glabellar lines, located between th
- Lack of Options for Darker Skin Types Hinder Use of Tinted Sunscreenshttps://practicaldermatology.com/news/tinted-sunscreens-lack-options-for-darker-skin-hindering-use/2461156/The lack of tinted sunscreen options for darker skin tones may discourage many people from using these products. This is the main message from a new analysis of consumer preferences of over-the-counter tinted sunscreen products. Sixty-two percent of tinted sunscreen products are only av
- Blueberry Extract May Improve Wound Healinghttps://practicaldermatology.com/news/blueberry-extract-may-improve-wound-healing/2461152/Treating wounds with an extract taken from wild blueberries may improve healing, according to a new study presented at the American Physiological Society’s annual meeting at Experimental Biology 2022. Researchers from the University of Maine previously found that a phenolic extrac
- Scientists Discover Gene Mutation That Signals Aggressive Melanomahttps://practicaldermatology.com/news/scientists-discover-gene-mutation-that-signals-aggressive-melanoma/2461149/Patients whose melanoma tumors have an ARID2 mutation may have a more aggressive cancer and may need to be treated differently, according to a study published in Cell Reports. &l
- Dermatological Society of New Jersey Kicks Off Virtual Conference Saturdayhttps://practicaldermatology.com/news/dermatological-society-of-new-jersey-kicks-off-virtual-conference-saturday/2461147/The DSNJ annual educational conference is a hybrid event this year, with in person as well as online conference experiences open to attendees across the US. The conference is Saturday, April 9. Penn Medicine Princeton Health, accredited by the Medical Society of New Jersey, designa
- Boehringer Ingelheim’s Effisayil Offers Sustained Relief from GPP Flareshttps://practicaldermatology.com/news/boehringer-ingelheims-effisayil-offers-sustained-releif-from-gpp-flares/2461143/Effisayil (Spesolimab) clears skin pustules in patients with generalized pustular psoriasis (GPP) flares within the first week after treatment, and these benefits are sustained over 12 weeks, according to data presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Bost
- AbbVie: Rinvoq Hits AD Treat-to-Target Aims as Early as Week 2https://practicaldermatology.com/news/abbvie-rinvoq-hits-ad-treat-to-target-aims-as-early-as-week-2/2461142/Treatment with Rinvoq® (upadacitinib) 15mg or 30mg allows patients to rapidly achieve their initial three-month acceptable treatment target goal at Week 2, with consistent achievement through Week 16, results of a new analysis show. Using the framework of the recently developed evidence-based
- Aquavit Submits NDA for New Neurotoxinhttps://practicaldermatology.com/news/aquavit-submits-nda-for-new-neurotoxin/2461141/Aquavit Pharmaceuticals, Inc. has submitted its IND for a new botulinum toxin (DTX-021) to the FDA for approval. The company also unveiled its development programs at the Annual meeting of the American Academy of Dermatology in Boston. DTX-021, a botulinum toxin type A drug intende
- Timber's Topical Isotretinoin Shows Benefit Across CI Subtypeshttps://practicaldermatology.com/news/timbers-topical-isotretinoin-shows-benefit-across-ci-subtypes/2461131/TMB-001, a topical isotretinoin formulated using Timber Pharmaceuticals’ patented IPEG™ delivery system, shows benefit in the treatment of congenital ichthyosis (CI), regardless of the subtype. Findings are being presented in a late-breaking presentation of a sub-analysis of the Phase